Recommended Reading
This information is intended for U.S. Healthcare Professionals only.
For additional information on COLAZAL® (balsalazide disodium) Capsules 750mg and its use in ulcerative colitis, please see the following list of references:
Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892-895.
Baron JH, Connell AM, Lennard-Jones JE, Avery Jones F. Sulfasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;1:1094-1096.
Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck & Co., Inc; 1999:307.
Das KM, Eastwook MA, McManus JPH, Sircus W. Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491-495.
Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982;14:405-408.
Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992;6(4):479-485.
Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992;6:51-59.
Green JRB, Gibson JA, Kerr GD, et al. and The ABACUS Investigator Group. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther. 1998;12:1207-1216.
Green JRB, Lobo AJ, Holdsworth CD, et al. and The ABACUS Investigator Group. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology. 1998;114:15-22.
Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002;16(1):61-68.
Green JR, Swan CH, Rowlinson A, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther. 1992;6(5):647-652.
Hanauer SB. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999;44(4):455.
Hanauer SB. Inflammatory bowel disease.Drug Ther. 1996;334(13):841-848.
Hanauer SB, Stathopoulos B. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991;6:192-219.
Jarnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut. 1994;35:1155-1158.
Kellock TD, White B. Prognosis in ulcerative colitis. Gastroenterologia. 1957;88:13-21.
Klotz U, Maier K, Fischer C, Keinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980;303:1499-1502.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterology. 1997;92(2):204-211.
Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001;49(6):783-789.
Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4) g in the treatment of active, mild to moderate ulcerative colitis. Am J Gastroenterology. 2002;97:1398-1407.
Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther. 2002;16(1):69-77.
McIntyre PB, Lennard-Jones JE. Reversal with balsalazide of infertility caused by sulphasalazine. Br Med J. 1984;288:1652-1653.
McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH, Thornton PC. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther. 1988;2(3):237-243.
Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet. 1965;1:185-188.
Muijsers Richard BR, Goa Karen L. Balsalazide: A review of its therapeutic use in mild-to-moderate ulcerative colitis.Drugs. 2002; 62 (11): 1689-1705
Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196-200.
Prakash A, Spencer CM. Balsalazide. Drugs. 1998;56(1):83-89.
Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology. 2000;118;4(pt 1):A756.
Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild to moderate ulcerative colitis. Am J Gastroenterology. Accepted for Publication.
Ragunath K, Williams JG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001;15(10):1549-1554.
Rice-Oxley JM, Truelove SC. Ulcerative colitis: course and prognosis. Lancet. 1950;1:163-166.
Shmueli E, Record CO. Adverse effects of the aminosalicylates. Adverse Drug Reac Bull. 1994;165:623-626.
Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983;28:833-842.
Yang Y, Su CG, Deren J, Lewis JD, Katzka D, Lichtenstein GR. Balsalazide as salvage therapy for mesalamine failure/intolerance in patients with ulcerative colitis. Am J Gastroenterology. 2001;96(9):S313. Abstract.
COLAZAL® (balsalazide disodium) Capsules 750 mg are indicated for the treatment of mildly to moderately active Ulcerative Colitis in patients 5 years of age and older.
COLAZAL does not relieve symptoms in all patients; your patients' results may vary. In four well-controlled clinical trials, patients receiving a COLAZAL dose of 6.75g/day most frequently reported the following events
(reporting frequency > 3%): headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to
placebo. In the pediatric trial, patients most frequently reported the following adverse events: headache (15%), abdominal pain upper (13%), abdominal pain (12%), vomiting (10%), diarrhea (9%), colitis ulcerative (6%),
nasopharyngitis (6%) and, pyrexia (6%). COLAZAL is contraindicated in patients with a hypersensitivity to salicylates or the components of COLAZAL capsules or balsalazide metabolites. The safety and effectiveness of
COLAZAL beyond 8 weeks in children (ages 5-17 years) and 12 weeks in adults have not been established.
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: